GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.10
Bid: 5.00
Ask: 5.20
Change: -0.10 (-1.92%)
Spread: 0.20 (4.00%)
Open: 5.15
High: 5.16
Low: 5.10
Prev. Close: 5.20
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Covid concerns in China drag stocks lower

Thu, 29th Dec 2022 12:14

(Alliance News) - Stock prices in London at midday continued to be weighed down by the worrying surge in Covid-19 cases as China swiftly re-opens from three years of strict lockdown measures.

"The good news with China's re-opening is that it should boost global growth. The bad news with China's reopening is that it will not only boost global growth, but also energy and commodity prices - hence inflation, the interest rate hikes from central banks and potentially the global Covid cases – which could then give birth to a new, and a dangerous Covid variant, which would, in return, bring the restrictive Covid measures back on the table, and hammer growth," said Ipek Ozkardeskaya at Swissquote Bank.

The FTSE 100 index was down 9.35 points, or 0.1%, at 7,487.84. The FTSE 250 was down 61.52 points, or 0.3% at 18,823.98, and the AIM All-Share was down 1.11 points, or 0.1%, at 831.17.

The Cboe UK 100 was down 0.2% at 748.97, the Cboe UK 250 down 0.4% at 16,295.30, and the Cboe Small Companies down 0.2% at 13,104.65.

Hospitals across China have been overwhelmed by an explosion of Covid cases following Beijing's decision to lift strict rules that had largely kept the virus at bay. 

On Monday, the country said it would bring an end to mandatory quarantine on arrival – prompting many jubilant Chinese citizens to make plans to travel abroad. In response, the US and a number of other countries announced they would require negative Covid tests for all travellers from mainland China.

Stocks in New York were called higher after Wednesday's steep sell-off. The Dow Jones Industrial Average was called up 0.2%, the S&P 500 index up 0.5%, and the Nasdaq Composite up 0.7% on Thursday. The indices closed down 1.1%, 1.2% and 1.4%, respectively, on Wednesday.

interactive investor's Victoria Scholar said continued worries about the performance of 'big tech', fears of a recession, rising interest rates, and China's complex Covid situation were weighing on Wall Street.

In London, Antofagasta fell 1.0%, after the miner reported that access to its Los Pelambres operation in Chile is being blocked by a group of people, affecting the transport of critical supplies and personnel to the mine site.

Antofagasta explained that the group is requesting compensation to clear access but added that, to date, there has been no material impact on production.

"The authorities are working to clear the blockade, and the company is engaging with them and representatives of the local communities to jointly resolve the situation," Antofagasta said.

Allergy Therapeutics plunged 52% after it said its shares will be suspended from trading next week, due to delays in completing the audit of its annual results.

Back in September, Allergy Therapeutics announced its unaudited preliminary results for the financial year that ended June 30. It sunk to a pretax loss of GBP12.7 million from a profit of GBP3.7 million the year prior. Revenue dropped to GBP72.8 million from GBP84.3 million.

"It is not aware of any material change that will be required to be made to the results, and it is actively working to finalise the audit and publication of its annual report and accounts," Allergy Therapeutics said.

Kazera Global dropped 22%. It also said its results will not be published before the end of the year, due to delays at its wholly-owned subsidiary African Tantalum.

The diamond and rare earths explorer now expects to release its results for the financial year that ended June 30 during February. As a result, its shares will be suspended from trading on AIM in London from Tuesday next week, the first trading day of 2023.

Tekcapital jumped 8.2%. It said investee Innovative Eyewear licensed outdoor brand Eddie Bauer for its smart eyewear collection through an agreement with Authentic Brands.

The company described the contract as a "multi-year, global licensing agreement", without providing financial details. The Eddie Bauer smart eyewear collection is expected to launch in 2023.

Index operator FTSE Russell revealed on Wednesday that Johnson Matthey will return to the FTSE 100 next week as part of index changes stemming from the acquisition of home repairs company Homeserve.

Johnson Matthey had been dumped from the FTSE 100 just over a year ago following an index review. Shares in the speciality chemicals firm were down 1.0% at midday on Thursday.

Early Thursday afternoon in Europe, the CAC 40 index in Paris was up 0.1%, while the DAX 40 in Frankfurt was up 0.2%.

The pound was quoted at USD1.2026 at midday on Thursday in London, down a touch compared to USD1.2029 at the close on Wednesday.

The euro stood at USD1.0633, higher against USD1.0617. Against the yen, the dollar was trading at JPY133.75, lower compared to JPY134.23.

Brent oil was quoted at USD83.00 a barrel at midday in London on Thursday, up from USD82.87 late Wednesday. Gold was quoted at USD1,806.05 an ounce, higher against USD1,801.04.

Still to come on Thursday's economic calendar, there are US weekly unemployment insurance claims at 1330 GMT.

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2022 Alliance News Ltd. All Rights Reserved.

More News
25 Sep 2019 11:26

Allergy Therapeutics Looking To Chinese Market As It Swings To Profit

Allergy Therapeutics Looking To Chinese Market As It Swings To Profit

Read more
27 Jun 2019 10:07

Allergy Therapeutics earnings set to top expectations

(Sharecast News) - Biotechnology group Allergy Therapeutics told investors on Thursday that 2019 full-year earnings looked set to come in ahead of market expectations.

Read more
19 Jun 2019 13:39

Allergy Therapeutics Hires Former Advanced Medical Solutions CFO

(Alliance News) - Allergy Therapeutics PLC on Wednesday said it has appointed Mary Tavener as a non-executive director with immediate effect.The biotechnology company said Tavener has in 19

Read more
20 May 2019 13:42

Allergy Therapeutics Vaccine Helps Dust Mite Allergy Symptoms In Study

LONDON (Alliance News) - Allergy Therapeutics PLC on Monday said its Acarovac MPL vaccine improved dust mite allergy symptoms during a phase one study.The AM101 study, which was open-label

Read more
20 May 2019 11:00

Allergy Therapeutics flags positive outcomes from recent treatment trial

(Sharecast News) - Biotechnology company Allergy Therapeutics announced positive Phase 1 safety and tolerability results of subcutaneous 'Acarovac MPL' (monophosphoryl lipid A) in patients with house dust mite-induced allergic rhinoconjunctivitis on Monday.

Read more
25 Apr 2019 10:01

Allergy Therapeutics eyes 2020 start for hay fever inoculation trials

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics will kick off phase III trials of its short-course inoculation for grass pollen-induced hay fever in the second half of 2020 following a successful round of meetings with German and American regulatory bodies.

Read more
18 Mar 2019 10:44

WINNERS & LOSERS SUMMARY: Footasylum Rises On "Generous" JD Offer

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - Tinto, up 2.3%, Group, up in

Read more
18 Mar 2019 10:06

Allergy Therapeutics Surprised As Vaccine Trial Fails Primary Endpoint

LONDON (Alliance News) - Allergy Therapeutics PLC on Monday said a phase three trial of its birch pollen allergy vaccine did not meet its primary endpoint.Shares in Allergy Therapeutics 43%

Read more
18 Mar 2019 08:51

Allergy Therapeutics shares plunge after disappointing clinical trial

(Sharecast News) - Shares in biotechnology company Allergy Therapeutics were plunging on Monday morning, after it announced disappointing top-line results from the phase 3 clinical trial 'B301' of its new adjuvanted birch allergoid product.

Read more
6 Mar 2019 11:13

Allergy Therapeutics Interim Profit Rises 67% On Higher Revenue

LONDON (Alliance News) - Allergy Therapeutics PLC on Wednesday reported significantly higher profit for the first six months of its financial year as revenue rose and research costs were the to of

Read more
6 Mar 2019 10:19

Allergy Therapeutics profits rise as it spends less on R&D

(Sharecast News) - Specialty pharmaceutical group Allergy Therapeutics announced its unaudited interim results for the six months ended 31 December on Wednesday, reporting a 10.6% improvement in revenue on both a reported and constant currency basis, to £46.7m.

Read more
16 Jan 2019 12:26

Allergy Therapeutics First Half Meets Forecasts On European Growth

LONDON (Alliance News) - Allergy immunology vaccines developer Allergy Therapeutics PLC said Wednesday trading in the first half was in line with expectations.Allergy Therapeutics expects -

Read more
16 Jan 2019 08:51

Allergy Therapeutics sees good first-half progress

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics updated the market for the six months ended 31 December on Wednesday, reporting that it was trading in line with board expectations.

Read more
27 Nov 2018 13:12

Allergy Therapeutics Continues To Perform Well, Revenue Up "Strongly"

LONDON (Alliance News) - Allergy Therapeutics PLC said Tuesday it has continued to perform well, with revenue up "strongly" from the prior year and sales in line with market financial to

Read more
27 Nov 2018 10:05

Allergy Therapeutics boosted by strong German performance

(Sharecast News) - Biotechnology company Allergy Therapeutics has seen revenues increase throughout the first half of its trading year thanks to an improved market share for its allergy vaccines on the continent.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.